The cancer immunotherapies will be developed and commercialized by using Rigel’s small molecule TGF beta receptor kinase inhibitors range. Through the partnership, Bristol-Myers Squibb will secure exclusive, global
Fundación MEDINA is a non-profit research organization formed through a private-public partnership between the Government of Andalucía (Spain), the University of Granada and Merck Sharp and Dohme de
Under the terms of consent agreement, the Swiss pharmaceutical company will divest all assets related to its BRAF and MEK inhibitor drugs to Array BioPharma to settle charges
MedImmune and NIST have inked a five-year agreement to this effect. As per the terms of the agreement, MedImmune is providing first-year funding for seven NIST postdoctoral scientists,
The company estimates the FDA decision for the sNDA in June 2015 based on the anticipated Prescription Drug User Fee Act (PDUFA) action date. Pfizer Global Innovative Pharmaceuticals
The acquisition forms a part of the company’s strategy to become a significant global biopharmaceutical company with drug discovery and clinical development capabilities for generating medicines. With this
Financed through a combination of bank debt and bonds, the acquisition amounts to about $158 for each of Salix’s outstanding shares, and will be followed by a merger
For the NDA, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of 11 August 2015. Cobimetinib is a specific MEK inhibitor discovered by
Malaysia is the 20th country to approve the company’s Phase III trial, which has now enrolled more than 350 patients with advanced primary, not yet treated, head and
Currently, Questcor operates as the autoimmune and rare diseases business of Mallinckrodt Pharmaceuticals. In Canada, Synacthen Depot is approved for therapeutic use in patients diagnosed with many difficult-to-treat
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.